293 related articles for article (PubMed ID: 14744396)
1. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
Hao LC; Zhang LZ
Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
[No Abstract] [Full Text] [Related]
2. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
3. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B
Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
5. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
6. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
8. [Resistance to rituximab and CD20 mutation].
Terui Y; Hatake K
Nihon Rinsho; 2007 Jan; 65 Suppl 1():416-23. PubMed ID: 17474440
[No Abstract] [Full Text] [Related]
9. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
[TBL] [Abstract][Full Text] [Related]
11. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
Kollmar O; Becker S; Schilling MK; Maurer CA
Transplantation; 2002 Feb; 73(4):669-70. PubMed ID: 11889454
[No Abstract] [Full Text] [Related]
12. Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.
Esmaeli B; Murray JL; Ahmadi MA; Naderi A; Singh S; Romaguera J; White CA; McLaughlin P
Arch Ophthalmol; 2002 Sep; 120(9):1225-7. PubMed ID: 12215104
[No Abstract] [Full Text] [Related]
13. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.
Schmitz K; Brugger W; Weiss B; Kaiserling E; Kanz L
Br J Haematol; 1999 Aug; 106(2):571-2. PubMed ID: 10460626
[No Abstract] [Full Text] [Related]
14. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
Tobinai K
Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
[TBL] [Abstract][Full Text] [Related]
15. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
16. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
17. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
[No Abstract] [Full Text] [Related]
19. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection.
Spina M; Sparano JA; Jaeger U; Rossi G; Tirelli U
AIDS; 2003 Jan; 17(1):137-8. PubMed ID: 12478085
[No Abstract] [Full Text] [Related]
20. Rituximab in cutaneous B-cell lymphoma: a report of two cases.
Sabroe RA; Child FJ; Woolford AJ; Spittle MF; Russell-Jones R
Br J Dermatol; 2000 Jul; 143(1):157-61. PubMed ID: 10886152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
